Clinical Trials Logo

ALK+ Advanced NSCLC clinical trials

View clinical trials related to ALK+ Advanced NSCLC.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03596866 Active, not recruiting - ALK+ Advanced NSCLC Clinical Trials

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

ALTA-3
Start date: April 19, 2019
Phase: Phase 3
Study type: Interventional

Brigatinib is a medicine that binds to the surface of tumor cells in some cancers and delivers a dose of chemotherapy directly to the tumor. In this study, participants will be people with non-small-cell lung cancer (NSCLC for short). The main aim of the study is to learn if brigatinib stops the tumors from growing, or if the tumors have shrunk or disappeared, compared to a medicine called alectinib. At the first visit, the study doctor will check who can take part. Participants who can take part will be picked for 1 of 2 treatments by chance: - Brigatinib tablets - Alectinib capsules All participants will take brigatinib or alectinib at about the same time every day. They will continue with treatment throughout the study unless their cancer gets worse, they have side effects from the treatment, they leave the study for certain reasons, or the study is stopped. After stopping treatment, participants will visit the study clinic for a check-up 30 days later.